Home>>Signaling Pathways>> GPCR/G protein>> 5-HT Receptor>>Cerlapirdine

Cerlapirdine Sale

(Synonyms: SAM-531; PF-05212365) 目录号 : GC63961

Cerlapirdine (SAM-531, PF-05212365) 是一种选择性和有效的 5-羟色胺 6 (5-HT6) 受体的完全拮抗剂。Cerlapirdine 具有研究阿尔茨海默病的潜力。

Cerlapirdine Chemical Structure

Cas No.:925448-93-7

规格 价格 库存 购买数量
5 mg
¥1,980.00
现货
10 mg
¥3,150.00
现货
25 mg
¥6,210.00
现货
50 mg
¥9,900.00
现货
100 mg
¥16,200.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

产品描述

Cerlapirdine (SAM-531, PF-05212365) is a selective and potent full antagonist of the 5-hydroxytryptamine 6 (5-HT6) receptor. Cerlapirdine has the potential for researching the Alzheimer’s disease[1].

[1]. Tse S, et al. Disposition and metabolic profiling of [(14)C]cerlapirdine using accelerator mass spectrometry. Drug Metab Dispos. 2014;42(12):2023-2032.

Chemical Properties

Cas No. 925448-93-7 SDF Download SDF
别名 SAM-531; PF-05212365
分子式 C22H23N3O3S 分子量 409.5
溶解度 DMSO : 41.67 mg/mL (101.76 mM; ultrasonic and warming and adjust pH to 3 with HCl and heat to 60°C) 储存条件 4°C, protect from light
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 2.442 mL 12.21 mL 24.42 mL
5 mM 0.4884 mL 2.442 mL 4.884 mL
10 mM 0.2442 mL 1.221 mL 2.442 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置

Research Update

Disposition and metabolic profiling of [(14)C]Cerlapirdine using accelerator mass spectrometry

Drug Metab Dispos 2014 Dec;42(12):2023-32.PMID:25217486DOI:10.1124/dmd.114.059675.

Cerlapirdine (SAM-531, PF-05212365) is a selective, potent, full antagonist of the 5-hydroxytryptamine 6 (5-HT6) receptor. Cerlapirdine and other 5-HT6 receptor antagonists have been in clinical development for the symptomatic treatment of Alzheimer's disease. A human absorption, distribution, metabolism, and excretion study was conducted to gain further understanding of the metabolism and disposition of Cerlapirdine. Because of the low amount of radioactivity administered, total (14)C content and metabolic profiles in plasma, urine, and feces were determined using accelerator mass spectrometry (AMS). After a single, oral 5-mg dose of [(14)C]Cerlapirdine (177 nCi), recovery of total (14)C was almost complete, with feces being the major route of elimination of the administered dose, whereas urinary excretion played a lesser role. The extent of absorption was estimated to be at least 70%. Metabolite profiling in pooled plasma samples showed that unchanged Cerlapirdine was the major drug-related component in circulation, representing 51% of total (14)C exposure in plasma. One metabolite (M1, desmethylcerlapirdine) was detected in plasma, and represented 9% of the total (14)C exposure. In vitro cytochrome P450 reaction phenotyping studies showed that M1 was formed primarily by CYP2C8 and CYP3A4. In pooled urine samples, three major drug-related peaks were detected, corresponding to cerlapirdine-N-oxide (M3), Cerlapirdine, and desmethylcerlapirdine. In feces, Cerlapirdine was the major (14)C component excreted, followed by desmethylcerlapirdine. The results of this study demonstrate that the use of the AMS technique enables comprehensive quantitative elucidation of the disposition and metabolic profiles of compounds administered at a low radioactive dose.